KD-3010
| 中文名称 | KD-3010 |
|---|---|
| 中文同义词 | 化合物 T11747;化合物KD-3010 |
| 英文名称 | KD-3010 |
| 英文同义词 | KD-3010;KD 3010,KD3010 |
| CAS号 | 934760-92-6 |
| 分子式 | C30H33F3N2O8S2 |
| 分子量 | 670.72 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 934760-92-6.mol |
| 结构式 |  |
KD-3010 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
|
PPARδ
|
To determine whether PPARδ agonists are beneficial in experimental liver fibrosis, mice are treated orally with a PPARδ agonist, KD-3010, or with the well-validated PPARδ agonist GW501516. KD-3010, but not GW501516, shows hepatoprotective and antifibrotic effects in liver fibrosis induced by carbon tetrachloride (CCl 4 ) or bile duct ligation (BDL). Liver injury is induced by repeated injections of CCl 4 , and mice are treated daily with vehicle, the widely used PPARδ agonist GW501516, or the PPARδ agonist KD-3010 by oral gavage. Control oil-injected mice do not show any liver damage. Liver injury consisting of hepatocyte death and inflammation is seen in the vehicle- or GW501516-treated group injected with CCl 4 on H&E-stained liver sections but is markedly reduced in the KD3010-treated group.